Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29681972 | 1.00 | GRM5 (1.00) | GRM5POLB | |
| SCHEMBL3677412 | 0.89 | GRM5 (0.80) | GRM5 | |
| SCHEMBL2482825 | 0.86 | GRM5 (1.00) | GRM5 | |
| SCHEMBL26673948 | 0.80 | GRM5 (0.66) | GRM5POLB | |
| SCHEMBL26673961 | 0.80 | GRM5 (0.66) | GRM5POLB | |
| SCHEMBL14132974 | 0.79 | GRM5 (0.85) | GRM5 | |
| SCHEMBL5924064 | 0.78 | GRM5 (1.00) | GRM5 | |
| SCHEMBL14132564 | 0.78 | GRM5 (0.91) | GRM5POLB | |
| SCHEMBL5924170 | 0.78 | GRM5 (1.00) | GRM5 | |
| SCHEMBL5924104 | 0.76 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| US-20150141462-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | claimed |
| WO-2013188465-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE | ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITY (US) | 2013-12-19 | — | — | WO | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | disclosed |
| US-12485117-B2 | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin | WYLDER NATION FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3762034-B1 | A FATTY ACID AMIDE HYDROLASE (FAAHI) INHIBITOR FOR USE IN INHIBITING THE CELLULAR ACCUMULATION OF A SPHINGOLIPID IN A SUBJECT THAT HAS LYSOSOMAL STORAGE DISEASE OR DISORDER | WYLDER NATION FOUND (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250057838-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB1 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING DISEASES AND DISORDERS CHARACTERIZED BY ABNORMAL CELLULAR ACCUMULATION OF SPHINGOLIPIDS SUCH AS SPHINGOMYELIN | WYLDER NATION FOUNDATION | 2025-02-20 | — | — | US | disclosed |
| US-12023332-B2 | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin | WYLDER NATION FOUNDATION (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | disclosed |
| WO-2011056849-A1 | METHODS OF TREATING ELEVATIONS IN MTOR SIGNALING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7531541-B2 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531541-B2 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY | 2007-09-06 | — | — | US | disclosed |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY | 2007-09-06 | — | — | US | disclosed |
| WO-2007035823-A2 | PARTIAL MGLUR5 ANTAGONISTS AND METHODS OF USE THEREOF | MOLECULAR NEUROIMAGING, LLC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060281803-A1 | Pyrazole modulators of metabotropic glutamate receptors | MERCK & CO., INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2005030128-A2 | PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023332-B2 | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin | SMPD1, GBA1, SMPD3 | GRM5 1189/4885POLB 3826/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GRM5 1/4885POLB 4074/4885 |
| US-12485117-B2 | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin | SMPD1, GBA1, SMPD3 | GRM5 1189/4885POLB 3826/4885 |
| US-20250057838-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB1 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING DISEASES AND DISORDERS CHARACTERIZED BY ABNORMAL CELLULAR ACCUMULATION OF SPHINGOLIPIDS SUCH AS SPHINGOMYELIN | SMPD1, GBA1, SMPD3 | GRM5 1189/4885POLB 3826/4885 |
| US-20060281803-A1 | Pyrazole modulators of metabotropic glutamate receptors | GRM5, GRM3, GRIK5 | GRM5 1/4885POLB 4342/4885 |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | GRM5, GRIK5, GRM1 | GRM5 1/4885POLB 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.